FAB-001

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H13F2NO3
Molecular Weight	293.2654
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCC1=CC(O)=C(OC2=CC=C(C=C2F)C(N)=O)C=C1F

InChI

InChIKey=QUHARGDBJJUOEB-UHFFFAOYSA-N

InChI=1S/C15H13F2NO3/c1-2-8-6-12(19)14(7-10(8)16)21-13-4-3-9(15(18)20)5-11(13)17/h3-7,19H,2H2,1H3,(H2,18,20)

HIDE SMILES / InChI

Molecular Formula	C15H13F2NO3
Molecular Weight	293.2654
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial enoyl-[acyl-carrier-protein] reductase 8	Inhibitor 8,504		12.0 nM [IC50]

Substance Class	Chemical
Record UNII	B52RPV7VRM
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

FAB001

Preferred Name

English

FAB-001

Common Name

English

BENZAMIDE, 4-(4-ETHYL-5-FLUORO-2-HYDROXYPHENOXY)-3-FLUORO-

Systematic Name

English

MUT056399

Code

English

MUT-056399

Code

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CAS

1269055-85-7

PRIMARY

SMS_ID

300000041507

PRIMARY

MANUFACTURER PRODUCT INFORMATION

FAB-001

PRIMARY

Biological Activity of MUT056399:MUT056399 is a highly potent inhibitor of the FabI enzyme of both S. aureus and E. coli with 50% inhibitory concentration IC50s of 12 nM and 58 nM, respectively.;IC50 value: 12 nM (for S. aureus), 58 nM (for E. coli);Target: FabI enzyme;in vitro: MUT056399 is a highly potent new inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. MUT056399 is very active against S. aureus strains, including methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), linezolid-resistant, and multidrug-resistant strains, with MIC90s between 0.03 and 0.12 .MU.g/ml. MUT056399 is also active against coagulase-negative staphylococci, with MIC90s between 0.12 and 4 .MU.g/ml. MUT056399 is very active against the 118 S. aureus strains tested, including MSSA and MRSA isolates and linezolid-resistant and multidrug-resistant strains, with MIC90s between 0.03 and 0.12 .MU.g/ml.

FDA UNII

B52RPV7VRM

PRIMARY

PUBCHEM

44208849

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					D3R3P8KG3A

ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADPH) FABI (STAPHYLOCOCCUS AUREUS (STRAIN NCTC 8325))

TARGET -> INHIBITOR

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					B52RPV7VRM

FAB-001

ACTIVE MOIETY

Comments:

Originator: Mutabilis; Developer: FAB Pharma; Class: Antibacterial, Benzamide, Phenol, Phenyl ether, Small molecule; Mechanism of Action: Enoyl-ACP reductase inhibitor; Highest Development Phase: Phase I for Methicillin-resistant Staphylococcus aureus infections; Most Recent Events: 12 Sep 2012 Antimicrobial data from a Preclinical trial in Acinetobacter infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012), 17 Sep 2011 Pharmacokinetics data from a preclinical trial presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011), 07 May 2011 Pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy (ECCMID/ICC-2011)

Showing 1 to 1 of 1 entries

Previous1Next